05/13/2024
4:08 PM | TransCode Therapeutics (Filer)
| Form DEFA14A | |
05/10/2024
3:45 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/05/2024
3:51 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/13/2024
7:12 PM | Lind Global Fund II LP (Filed by)
TransCode Therapeutics (Subject)
| Form SC 13G/A | |
01/31/2024
3:33 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/22/2024
3:45 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
8:57 PM | TransCode Therapeutics (Filer)
| Form 424B4 | |
|
01/18/2024
11:15 PM | TransCode Therapeutics (Filer)
| Form EFFECT | |
01/18/2024
9:39 AM | TransCode Therapeutics (Filer)
| Form S-1/A | |
01/17/2024
6:06 AM | TransCode Therapeutics (Filer)
| Form S-1/A | |
01/11/2024
7:22 AM | TransCode Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
01/04/2024
11:41 AM | TransCode Therapeutics (Filer)
| Form DEFA14A | |
12/08/2023
3:56 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/08/2023
3:57 PM | TransCode Therapeutics (Filer)
| Form PRE 14A | |
12/07/2023
3:30 PM | Lind Global Fund II LP (Filed by)
TransCode Therapeutics (Subject)
| Form SC 13G | |
12/04/2023
4:07 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/01/2023
4:23 PM | TransCode Therapeutics (Filer)
| Form 424B5 | |
11/14/2023
3:40 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/26/2023
3:29 PM | TransCode Therapeutics (Filer)
| Form 424B5 | |
10/24/2023
7:05 AM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/02/2023
3:37 PM | Dudley Robert Michael (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/02/2023
3:39 PM | Fitzgerald Thomas A (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2023
4:26 PM | TransCode Therapeutics (Filer)
| Form 424B4 | |
09/26/2023
10:06 AM | TANG CAPITAL PARTNERS LP (Filed by)
TransCode Therapeutics (Subject)
| Form SC 13G | |
09/25/2023
11:15 PM | TransCode Therapeutics (Filer)
| Form EFFECT | |
09/22/2023
8:56 PM | TransCode Therapeutics (Filer)
| Form S-1/A | |
09/08/2023
8:54 PM | TransCode Therapeutics (Filer)
| Form S-1/A | |
08/29/2023
3:10 PM | TransCode Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
08/14/2023
3:31 PM | TransCode Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/04/2023
7:30 AM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/22/2023
5:23 PM | Dudley Robert Michael (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2023
3:16 PM | Dudley Robert Michael (Reporting)
TransCode Therapeutics (Issuer)
| Form 4/A | |
06/13/2023
3:16 PM | Dudley Robert Michael (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/08/2023
4:25 PM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/07/2023
4:29 PM | TransCode Therapeutics (Filer)
| Form 424B4 | |
06/06/2023
11:15 PM | TransCode Therapeutics (Filer)
| Form EFFECT | |
06/06/2023
12:11 PM | TransCode Therapeutics (Filer)
| Form S-1/A | |
05/22/2023
6:45 AM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/19/2023
7:06 PM | Calais Philippe (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/19/2023
7:06 PM | Dudley Robert Michael (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/19/2023
7:07 PM | Fitzgerald Thomas A (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Revolutionizing the Green Energy Space and Building Shareholder Value Along the Way (Ad) As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely! Learn how this American company is leading the lithium-ion revolution |
05/19/2023
7:08 PM | Marquet Magda (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/19/2023
7:09 PM | Manting Erik (Reporting)
TransCode Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/18/2023
8:15 AM | TransCode Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
